From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: APH

Search articles by EPIC code
EPIC APH
views

Alliance Pharma – product rights acquisition, looks good

Alliance Pharma (APH) has announced a $7.5 million acquisition from medical technology company Smith & Nephew, with CEO John Dawson emphasising “the acquisition will be immediately earnings enhancing, accretive to our underlying return on invested capital, and it fits well in our existing bedrock business operations”

EPIC APH
views

Alliance Pharma – despite Diclectin disappointment, still looking good, BUY

Speciality pharmaceutical company Alliance Pharma (APH) has announced results for the first half of 2017 and that “having delivered results in this period in line with expectations, and having a sound platform in place, we look forward to the second half and beyond with confidence" I agree and this offers a way to get a good solid low risk 15% return. Let me explain.

Page 2 of 5 (45 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments